Ratings
0
Nobody has rated this yet. Be the first!
Works
3
Erlotinib in lung cancer - molecular and clinical predictors of outcome
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia
Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates
